A Randomized, Open-label, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of a Novel Pharmaceutical Lipid-aspirin Complex Formulation (PL-ASA) at an 81 mg Dose

A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose

开始日期2021-04-28

申办/合作机构

PLx Pharma, Inc.

NCT04284397 / Recruiting早期临床1期IIT

Identification of Critical Thermal Environments for Aged Adults

This study evaluates critical environmental limits (temperature and humidity) above which older adults are unable to effectively thermoregulate. Participants will exercise in a series of different environmental conditions to identify combinations of temperature and humidity above which age-related physiological changes cause uncompensable heat stress, resulting in increased risk of heat illness.

开始日期2020-12-30

申办/合作机构

The Pennsylvania State University

NCT02989558 / Completed临床3期IIT

A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During Transcatheter Aortic Valve Implantation (TAVI) OperationS - the PTOLEMAIOS Study.

Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization in the cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and 30 days afterwards, than Clopidogrel plus ASA. This hypothesis will be investigated by measuring the number of High Intensity Transient Signals (HITS) as assessed with transcranial Doppler (TCD) on middle cerebral arteries.

开始日期2016-12-01

申办/合作机构

National & Kapodistrian University of Athens

100 项与阿司匹林/萘磺酸丙氧芬相关的临床结果

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的转化医学

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的专利（医药）

登录后查看更多信息

9,143

项与阿司匹林/萘磺酸丙氧芬相关的文献（医药）

2024-12-31·Platelets

Utility of VerifyNow to assess the immediate pharmacodynamic response of chewed and swallowed aspirin: comparison with aggregometry

Article

作者: Bliden, Kevin P ; Tantry, Udaya S ; Shah, Anika P ; Singh, Sahib ; Babu, Aravind D ; Gurbel, Paul A ; Parekh, Rueshil ; Kraft, Danielle ; Kundan, Parshotam

VerifyNow (VN) test is a less laborious method to assess pharmacodynamics (PD) compared to light transmittance aggregometry (LTA). VN assay has not been used to study the immediate PD effects of acetylsalicylic acid (ASA). Ten healthy volunteers were randomly assigned to a single 162 or 650 mg dose of chewed and swallowed ASA. Pharmacodynamic and pharmacokinetic measurements were performed at baseline and serially up to 60 min after ASA administration. Onset by VN was 20 ± 7 min with 162 mg and 13 ± 7 min with 650 mg ASA (p = .07). Onset by 1 mM AA-induced PA was 13 ± 12 min with 162 mg and 7 ± 3 min with 650 mg ASA (p=NS). VN correlated with AA-induced PA (r = 0.80, p < .001) and serum TxB₂ levels (r = 0.76, p < .001). 95% inhibition of serum TxB₂ was achieved at 38 ± 22 min and 22 ± 8 min with the 162 and 650 mg ASA, respectively (p = .08). The onset and extent of the antiplatelet effect of 650 mg ASA is numerically faster and greater than the 162 mg dose. VN identifies the onset, extent, and dose response to ASA therapy. The ease of using VN should facilitate multicenter PD investigations of ASA.

2024-12-01·Current Rheumatology Reviews

Study on the Expression and Potential Function of LncRNA in Peripheral Blood of Patients with Ankylosing Spondylitis

Article

作者: Xia, Liao ; Yi-Ping, Tang ; Ting, Yi ; Quan-Bo, Zhang ; Yu-Feng, Qing ; Fei, Dai ; Hong-Yuan, Xie

Background:Ankylosing spondylitis (AS) is an autoimmune disease that has the characteristics of difficult early diagnosis and a high disability rate.Objective:The objective of this study was to further explore the possible mechanism and potential function of lncRNA in AS.Methods:We used lncRNA microarray technology to detect the expression of lncRNA and mRNA in patients with active AS, stable patients, and healthy controls (HC). Afterward, bioinformatics analysis was conducted on differentially expressed genes. Seven differentially expressed lncRNAs were screened out for real-time fluorescent quantitative PCR (RT-qPCR), combined with various clinical indicators for correlation analysis, and the receiver operating characteristic (ROC) curve was used to analyze the potential of lncRNA as a diagnostic marker for AS.Results:The results showed that the expression levels of NR-037662 and ENST00000599316 in the AS subgroups were significantly higher than those in the HC group, while the expression levels of ENST00000577914 and ENST00000579003 were lower than those in the HC group. The expression levels of NR-003542 and ENST00000512051 in the ASA group were significantly higher than those in the ASS and HC groups, while NR-026756 was just the opposite. Spearman’s correlation analysis showed that the expression level of NR-003542 was positively correlated with Bath Ankylosing Spondylitis Functional Index (BASFI), Erythrocyte Sedimentation Rate (ESR), and high sensitivity C-Reactive Protein (hsCRP). The expression level of NR-026756 was negatively correlated with the Bath Ankylosing Spine Inflammatory Disease Activity Index (BASDAI), BASFI, ESR, hsCRP, and globulin (GLOB). In addition, it was also found that the ROC curve analysis of the 4 lncRNAs between the AS group (ASA group and ASS group) and the HC group were statistically significant, and the area under the curve (AUC) of NR-037662, ENST00000599316, ENST00000577914, and ENST00000579003 was 0.804, 0.812, 0.706, and 0.698, respectively.Conclusion:It was found that these differentially expressed lncRNAs of AS may be involved in the occurrence and development of the disease. Among them, NR-037662, ENST00000599316, ENST00000577914, and ENST00000579003 might have the potential to become AS diagnostic molecular markers. Moreover, NR -003542, ENST00000512051, and NR-026756 might have the potential to be indicators of disease activity.

2024-12-01·Journal of Orthopaedics

Socioeconomic area deprivation index is not associated with postoperative complications following revision total hip and knee joint arthroplasty

Article

作者: Chen, Shane Fei ; Buddhiraju, Anirudh ; Lin-Wei Chen, Tony ; Xiao, Pengwei ; Shimizu, Michelle Riyo ; Kwon, Young-Min ; RezazadehSaatlou, MohammadAmin ; Huang, Ziwei

IntroductionRevision hip and knee total joint arthroplasty (TJA) carries a high burden of postoperative complications, including surgical site infections (SSI), venous thromboembolism (VTE), reoperation, and readmission, which negatively affect postoperative outcomes and patient satisfaction. Socioeconomic area-level composite indices such as the area deprivation index (ADI) are increasingly important measures of social determinants of health (SDoH). This study aims to determine the potential association between ADI and SSI, VTE, reoperation, and readmission occurrence 90 days following revision TJA.Methods1047 consecutive revision TJA patients were retrospectively reviewed. Complications, including SSI, VTE, reoperation, and readmission, were combined into one dependent variable. ADI rankings were extracted using residential zip codes and categorized into quartiles. Univariate and multivariate logistic regressions were performed to analyze the association of ADI as an independent factor for complication following revision TJA.ResultsDepression (p = 0.034) and high ASA score (p < 0.001) were associated with higher odds of a combined complication postoperatively on univariate logistic regression. ADI was not associated with the occurrence of any of the complications recorded following surgery (p = 0.092). ASA remained an independent risk factor for developing postoperative complications on multivariate analysis.ConclusionAn ASA score of 3 or higher was significantly associated with higher odds of developing postoperative complications. Our findings suggest that ADI alone may not be a sufficient tool for predicting postoperative outcomes following revision TJA, and other area-level indices should be further investigated as potential markers of social determinants of health.

项与阿司匹林/萘磺酸丙氧芬相关的新闻（医药）

2023-07-06

·PRNewswire

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial. The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China. The bridging trial is intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC®) with Hexvix compared to white light cystoscopy in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese population. The clinical trial follows the same protocols for registration studies in countries where Hexvix already has market authorization. This study is being led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences. Professor Li Hanzhong, head of the Department of Surgery at Peking Union Medical College Hospital, is serving as the Principal Investigator, leading a team of top experts in the field of bladder cancer in China to carry out this study. Asieris plans to file a new drug application with the National Medical Products Administration (NMPA) in the future, pending clinical trial progress and meaningful data. Asieris Pharmaceuticals is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. In January 2021, Asieris entered into a license agreement with Photocure ASA to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan. In December 2021, 2021, Hexvix obtained initial clinical use in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, when the first patient received blue light cystoscopy with Hexvix at the Hainan General Hospital. The phase III clinical trial obtained approval from the NMPA in the first quarter of 2022 and Hexvix was subsequently included in the real-world clinical data pilot program. Read Asieris' full media release here: The trial is registered here: Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths in 2020.1b Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3 Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4 1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: , accessed [January 2022]. 2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657 3 Sievert KD et al. World J Urol 2009;27:295–300 4 Bladder Cancer. American Cancer Society. About Hexvix®/Cysview® (hexaminolevulinate HCl) Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions. Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer to for further information on our commercial partners. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , , For further information, please contact: Dan Schneider President and CEO Photocure ASA Email: [email protected] Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: [email protected] David Moskowitz Vice President, Investor Relations Photocure ASA Tel: +1 202 280 0888 Email: [email protected] Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected] The following files are available for download: SOURCE Photocure

临床3期引进/卖出

2023-05-29

·PRNewswire

Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023: Key Trends, Players and Top Deal Values

DUBLIN, May 29, 2023 /PRNewswire/ -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest in vitro diagnostics agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review in vitro diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering in vitro diagnostics partnering deals. The report presents financial deal term values for in vitro diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the in vitro diagnostics partnering field; both the leading deal values and most active in vitro diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 900 online deal records of actual in vitro diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of in vitro diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in in vitro diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading in vitro diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in vitro diagnostics dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostics deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of in vitro diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of in vitro diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific in vitro diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by in vitro diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in vitro diagnostics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of in vitro diagnostics technologies and products. Key benefits Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 provides the reader with the following key benefits: In-depth understanding of in vitro diagnostics deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual in vitro diagnostics contracts entered into by leading biopharma companies Identify most active in vitro diagnostics dealmakers since 2010 Insight into terms included in a in vitro diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 is intended to provide the reader with an in-depth understanding and access to in vitro diagnostics trends and structure of deals entered into by leading companies worldwide. In Vitro Diagnostics Partnering Terms and Agreements includes: Trends in in vitro diagnostics dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to in vitro diagnostics contract documents Leading in vitro diagnostics deals by value since 2010 Most activein vitro diagnostics dealmakers since 2010 In Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 900 in vitro diagnostics deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned HelixBind WuXi Biologics Aytu BioPharma Roka Bioscience Zora Biosciences Mesa Biotech Sensible Medical Innovations MyLabBox Sunnybrook Health Sciences Centre Unilabs AmpTec Glytec Nordic Biolabs Public Health England America's Choice Provider Network Clinical Genomics Clinical Reference Laboratory LifeScan American Medical Depot American Pathology Partners MagnaCare Lucence Advanced Biological Laboratories Advanced Cooling Therapy Advanced Dermatology and Cosmetic Surgery Group Massachusetts General Hospital Massachusetts Institute of Technology Massachusetts Life Sciences Center Accuscience Mayo Clinic Enzo Clinical Labs MicroCoat Biotechnologie BioTecon Diagnostics AliveCor Sintact Medical Systems PredictImmune Collective Medical Trivector Biomed XCellCure Sensocure Photocure ASA PAVmed Eckerd College Oxford Immunotec United Nations Children Fund United States Agency for International Development For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

诊断试剂

2023-05-04

·PRNewswire

Photocure ASA - Correction: Annual general meeting held

OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET). The minutes (corrected) from the general meeting setting out the resolved resolutions are attached hereto. For further information, please contact: Photocure CFO Erik Dahl Tel: + 47 450 55 000 Email: [email protected] About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , or . This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. The following files are available for download: SOURCE Photocure

100 项与阿司匹林/萘磺酸丙氧芬相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2023	N/A	心血管疾病	103	Low-dose ASA challenge (LDAC)	簾簾憲構選蓋醖觸窪窪(壓壓廠獵願獵網選選鑰) = 鑰遞願願顧鹹構遞蓋夢蓋鏇膚廠窪簾鏇夢襯選 (鹹衊願夢鏇淵觸憲醖壓 )	-	2023-08-25
				Acetylsalicylic acid	(鬱鏇窪築構壓繭醖餘窪) = 鏇衊簾繭鹹鏇齋衊夢顧遞夢衊襯餘齋淵網網淵 (簾願鹽糧簾蓋艱獵選衊 )
PREVENTLynch (ASCO2023)	N/A	遗传性非息肉病性结直肠癌	116	ASA users	膚遞蓋遞窪壓蓋積蓋鑰(簾願鬱顧繭淵簾顧淵蓋) = 壓壓願膚蓋獵鑰齋鏇艱鏇獵構窪鏇遞簾淵鹹觸 (顧餘襯範遞製構鑰鹹繭 )	-	2023-05-31
EHA2022	N/A	骨髓增生性疾病	69	ASA dosed once daily	(願鑰醖積艱鹽夢艱範鏇) = All-cause mortality was higher in the cohort 3 compared to the cohort 1 艱窪膚鏇觸積鑰襯膚願 (網選膚廠蓋壓鹽選憲鑰 )	-	2022-05-12
ASCO_GI2021	临床3期	遗传性非息肉病性结直肠癌	127	ASA users	遞憲醖顧壓淵獵顧淵願(醖膚艱淵醖淵網衊壓簾) = 觸築積鹽齋願艱淵繭顧蓋壓製鏇簾繭觸襯襯顧 (願餘齋壓淵鹹顧觸艱繭 )	-	2021-01-22
Pubmed \| J Cardiovasc Pharmacol Ther	N/A	-	830	Patients treated with ASA	鏇鏇繭壓醖糧窪鏇鹹築(窪網顧鏇範膚遞蓋窪醖) = 願蓋網餘願蓋廠艱願簾襯齋鏇鹽夢醖膚選鏇顧 (顧餘鬱齋艱遞簾憲膚構 )	-	2020-11-07
				Patients not treated with ASA	鏇鏇繭壓醖糧窪鏇鹹築(窪網顧鏇範膚遞蓋窪醖) = 構膚艱膚觸蓋壓網獵製襯齋鏇鹽夢醖膚選鏇顧 (顧餘鬱齋艱遞簾憲膚構 )
AAAAI2020	N/A	药物过敏反应	11	ASA 500mg	廠窪艱築衊襯壓醖築鏇(窪構構艱醖範鑰衊觸壓) = Group A patients reacted to the culprits in DPT and developed immediate urticaria (one reacted to paracetamol and metamizole and the other one to paracetamol and ibuprofen) 範膚膚範願廠鏇遞廠醖 (鬱簾鏇獵鏇襯願築壓構 ) 更多	积极	2020-02-01
				ASA 1000mg
ERSPC AARAU (AUA2019)	N/A	前列腺癌	4,314	ASA users	廠鹽築繭顧繭積醖窪淵(衊鹹蓋遞選膚鹹鹽獵鹽) = 網艱膚鹽鏇鏇壓鏇衊選範糧夢製艱糧網繭壓築 (繭鹹願鑰夢獵構築鹽製 ) 更多	-	2019-04-01
				non-users	廠鹽築繭顧繭積醖窪淵(衊鹹蓋遞選膚鹹鹽獵鹽) = 鹹鬱鹽夢壓觸構蓋艱鏇範糧夢製艱糧網繭壓築 (繭鹹願鑰夢獵構築鹽製 ) 更多
NCT01082874 (POISE-2, CTgov)	临床3期	心血管疾病	10,010	Active Clonidine+Active ASA (Active Clonidine and Active ASA)	壓製壓蓋醖艱鏇艱觸獵(憲構襯製鹹遞範蓋築獵) = 鹹窪襯糧齋構壓簾窪醖鑰積鏇淵鹽選衊構簾鹽 (遞壓淵襯醖膚廠齋遞顧, 遞蓋艱簾願顧膚簾膚構 ~ 夢製衊蓋蓋鹹積製鬱齋) 更多	-	2016-08-25
				Placebo ASA+Active Clonidine (Active Clonidine and Placebo ASA)	壓製壓蓋醖艱鏇艱觸獵(憲構襯製鹹遞範蓋築獵) = 憲蓋遞遞蓋壓鏇觸醖衊鑰積鏇淵鹽選衊構簾鹽 (遞壓淵襯醖膚廠齋遞顧, 網鬱餘繭築鹽選壓淵網 ~ 積鏇夢艱鏇膚顧鹹夢衊) 更多
AHNS2016	N/A	-	570	Continued ASA therapy	鹽鹹鏇獵製鏇鬱憲糧範(憲醖築選齋襯積選構鏇) = A total of 6 patients developed hematoma between both groups, and 1 (16.7%) required operative exploration 簾艱窪簾壓製憲襯窪遞 (積遞遞廠艱遞築淵齋窪 )	-	2016-07-16
				Naïve (no ASA therapy)
NCT01642238 (CTgov)	临床4期	急性冠状动脉综合征	15	Bivalirudin+ASA+Ticagrelor (Ticagrelor + ASA + Bivalirudin)	繭壓簾積醖築糧壓範選(廠夢願廠鏇艱鹹膚齋繭) = 憲範糧構衊觸鑰糧顧糧醖選餘鏇糧獵淵糧鹽觸 (願獵構築餘醖觸襯夢鹹, 網網簾艱憲憲範積繭壓 ~ 鬱窪醖醖構鹽夢構顧願) 更多	-	2016-07-11
				AS+Bivalirudin+Clopidogrel (Clopidogrel + ASA + Bivalirudin)	繭壓簾積醖築糧壓範選(廠夢願廠鏇艱鹹膚齋繭) = 淵齋願觸鏇糧憲選壓鏇醖選餘鏇糧獵淵糧鹽觸 (願獵構築餘醖觸襯夢鹹, 觸製淵艱築餘獵網鏇鹹 ~ 壓構淵範醖膚糧構鏇鏇) 更多